vision-biotech launches a new low dimer recombinant human NGAL

vision-biotech (VBT) has announced the launch of its recombinant NGAL protein. A new marker for the early diagnosis of acute kidney injury (AKI), VBT鈥檚 recombinant protein has low dimer content in relation to the monomer. Levels of NGAL can be seen to rise in the blood and urine, within 2 hours or less, during […]


vision-biotech demonstrates its commitment to biosensor market with the launch of a new grade of FAD-GDH

vision-biotech (VBT) has announced the launch of a next generation FAD-dependent Glucose Dehydrogenase (FAD-GDH) for blood glucose monitoring. For people with diabetes, it is critical that they are able to measure their blood glucose levels accurately.聽 This need for greater accuracy for end users, along with tightening regulatory requirements, is driving the development of […]